---
title: 'Funding Daily Summary: What Happened on November 15, 2026'
headline: Oyster raises $60 million for tau-degrader research
description: The London startup will use the Series A-2 financing to advance a preclinical
  Alzheimer’s candidate and other programs.
url: https://thebench.bio/news/funding/2026-11-15
topic: funding
date: '2026-11-15'
covers:
- '2026-11-15'
date_published: '2026-11-16T00:00:33Z'
date_modified: '2026-11-16T00:00:33Z'
tags:
- Industry
sources: 1
publisher: TheBench.Bio
---

# Funding Daily Summary: What Happened on November 15, 2026

**Oyster raises $60 million for tau-degrader research**

The London startup will use the Series A-2 financing to advance a preclinical Alzheimer’s candidate and other programs.

## Today in brief

Oyster Therapeutics secured $60 million in Series A-2 funding for its preclinical candidate, designed to degrade disease-linked tau. [1]

## Also worth knowing

- 4BIO Capital led the round, joined by Eli Lilly and other new and existing investors. CEO Rob Johnson said Oyster aims to take its tau degrader into clinical testing. [1]

## The day in numbers

- **$60 million**: Oyster Therapeutics’ Series A-2 financing [1]

## Sources

1. [Brain-Focused Startup Oyster Gets $60M to Beat the Size Problem for Small Molecule Degraders](<https://medcitynews.com/2026/11/oyster-therapeutics-tau-protein-degradation-alzheimers-neurodegenertion-startup-selftac-kesmalea/>), MedCity News, 2026-11-15

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://medcitynews.com/2026/11/oyster-therapeutics-tau-protein-degradation-alzheimers-neurodegenertion-startup-selftac-kesmalea/>
